Cell and Gene Therapies in Rheumatology – Disease Overview, Treatment Options and Future Market Assessment

Cell and Gene Therapies in Rheumatology Market Report Overview

The market size for cell and gene therapies (CGT) in rheumatic diseases by molecule type is estimated to be $24 million in 2024. Cell therapies will continue to dominate the CGT market in rheumatic diseases. This growth is attributed to the high number of cell therapy assets in the pipeline and increasing interest in rheumatic diseases due to the increasing prevalence and high unmet need, especially as the aging population increases.

Cell and Gene Therapies in Rheumatology Market Outlook 2024-2029 ($Million)

Buy the Full Report to Know More about the Cell and Gene Therapies in Rheumatology Market Forecast

Download a Free Sample Report

The cell and gene therapies in rheumatology market research report provides a comprehensive overview of cell and gene therapies (CGT) in rheumatology. The report focuses on the marketed CGT assets addressing rheumatic diseases as well as the top five rheumatic disease indications with the most CGT pipeline assets. This report will also aid clients in gaining insights into the competitive landscape of leading CGT agents in rheumatic diseases including launch date projections, analyst consensus forecasts, likelihood of approval analysis, pricing strategies, and commentary on current and future players. The report also includes an outlook of pricing and reimbursement assessment. Furthermore, the report includes commentary on the regulatory landscape of CGTs and the reimbursement environment.

Cell and Gene Therapies (CGT) in Rheumatology Market Dynamics

Various factors such as lack of interest or focus on rheumatology and the challenge of uptaking CGTs due to safety concerns can impact the CGT in rheumatology. Furthermore, pricing or access barriers, and lack of rheumatology-specific guidelines for CGT development also contribute to the previous factors.

Lack of interest or focus on rheumatology: Key Opinion Leaders (KOLs) have noted that pharmaceutical companies often prioritize diseases associated with high complexities and quality-of-life issues for patients. This prioritization can imply a lack of focus on diseases within the rheumatology space. However, given the high market potential and unmet need, KOLs are eager to see CGT therapies being developed in these indications.

Buy the Full Report to Know More about Cell and Gene Therapies (CGT) in Rheumatology Market Dynamics

Download a Free Sample Report

Cell and Gene Therapies (CGT) in Rheumatology – Current Treatment Options

The current marketed landscape for CGTs in rheumatology is composed solely of cell therapies focused primarily on rheumatic diseases affecting various connective tissues, such as OA (Osteoarthritis), graft versus host disease (GvHD), and cartilage degeneration. As these agents are currently marketed outside of the US, there is limited information regarding their clinical development and commercial positioning.

Of the four marketed cell therapies in rheumatology, all four are based on mesenchymal stem cells (MSCs). This is attributed to the research that has shown that these cells possess the capability to replace dead/damaged cells as well as transform into different cell types. However, key opinion leaders (KOLs) interviewed by GlobalData had varying opinions regarding the role of MSCs in OA and other indications.

Buy the Full Report to Know More about the Current Treatment Options of Cell and Gene Therapies (CGT) in Rheumatology
Download a Free Sample Report

Cell and Gene Therapies (CGT) in Rheumatology – Future Market Assessment

• Rheumatology disorders with the highest number of CGTs in the pipeline include a range of immunological/musculoskeletal diseases and transplant surgery-related complications. OA is the rheumatology disorder with the most CGTs in development. Other rheumatology disorders such as SLE/cutaneous lupus erythematosus (CLE)/lupus nephritis (LN), rheumatoid arthritis (RA), scleroderma, and various autoimmune disorders have a high number of CGT assets in development.
• Across the top five rheumatology indications, more than half of the molecule types for pipeline assets are cell therapies. KOLs noted that R&D toward the application of cell therapy in rheumatic diseases is further ahead than the application of gene therapy.

Buy the Full Report for More Insights into the Future Market Assessment of Cell and Gene Therapies (CGT) in Rheumatology

Download a Free Sample Report

Cell and Gene Therapies (CGT) in Rheumatology – Competitive Landscape

The key players in the CGT in rheumatology market are MediPost, Dong-A ST, Biostar, Stempeutics, Alkem, JCR, and Mesoblast among others.
Dong-a St’s Cartistem (OA) and Mesoblast/JCR’s remestemcel-L (GvHD) were the first CGT assets to receive traditional approval in the rheumatology market in 2012. This was followed by Biostar’s JointStem entry into the market in 2015. However, the rheumatology market has faced several CGT discontinuations. KOLs interviewed by GlobalData suggested that these discontinuations could be attributed to several factors such as high cost of development, lack of clinical efficacy, or companies rethinking entry into indications with existing treatment options.

Key Cell and Gene Therapies (CGT) in Rheumatology Companies
Buy the Full Report for More Company Insights into the Cell and Gene Therapies (CGT) in Rheumatology

Download a Free Sample Report

Scope

Overview of cell and gene therapies (CGT) in Rheumatology. The report focuses on the marketed CGT assets addressing rheumatic diseases as well as the top five rheumatic disease indications with the most CGT pipeline assets. Clients will gain insight into the competitive landscape of leading CGT agents in rheumatic diseases including launch date projections, analyst consensus forecasts, likelihood of approval analysis, pricing strategies, and commentary on current and future players. The report also includes outlook from three key opinion leaders in the 5EU, US, and Japan, and analyses key challenges and opportunities in the application of CGTs in rheumatic diseases. Additionally, the report includes commentary on the regulatory landscape of CGTs and on the reimbursement environment.

Key Highlights

Report deliverable includes a PowerPoint report.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the CGT in Rheumatology market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact rheumatic disease targeting CGT therapeutics market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.